Insulet Omnipod® 5

The Omnipod 5 system is Insulet’s newest insulin delivery system. It is largely similar to Insulet’s previous system, the Omnipod DASH Insulin Management System. However, the updated system includes Dexcom G6 compatibility and several other added features.

Your insurance may cover the cost of purchasing the Omnipod 5 system. Get in touch with our team of diabetes product experts to learn more.

Like other market-leading insulin pumps, you can buy the Omnipod 5 system from US MED.

As of April 2022, the FDA has only approved the Omnipod 5 system for use by people with type 1 diabetes. That may change in the future, as Insulet has released the results of a feasibility study on using this product with type 2 diabetes.

The Omnipod 5 does not have continuous glucose monitoring capabilities on its own. However, the system can wirelessly communicate with the Dexcom G6 CGM System.

The FDA has OK’d the Omnipod 5 system for people aged six years and older with type 1 diabetes.

The Omnipod 5 system communicates with the Dexcom G6 CGM. Through the SmartAdjust technology that is built into the Pod, the pump can automatically increase, decrease and pause delivery of insulin based on current and predicted glucose values from the CGM. The Omnipod 5 SmartBolus calculator is the software that can calculate a suggested bolus dose based on the carbohydrates entered by the user, most recent sensor glucose value, insulin on board (IOB), correction factor, insulin to carbohydrate ratio, and the target glucose value.

Yes! This integration is the first of its kind and studies show that using this automated insulin delivery (AID) system (1,2) increases glucose time in range for children and adults with type 1 diabetes(5,6) by 11%.** Also patients using the AID systems saw reduced hypoglycemic range by 2%. Both of these factors could leads to better overall health for those living with type 1 diabetes.

**Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, CO 2. Section of Pediatric Endocrinology, Yale SChool of Medicine, New Haven, CT: 3 Section of Pediatric Diabetes and Endocrinology, Stanford School of Medicine, Palo Alto, CA; 5 Upstate Medical University, Syracuse, NY; 6. Division of Endocrinology, Center for Diabetes Technology, University of Virginia, Charlottesville, VA; Insulet Corp, Acton, MA